Overactive bladder treatments show differences in efficacy
Differences between antimuscarinic treatments for overactive bladder syndrome are beginning to emerge.
A meta-analysis conducted by UK researchers was presented at the European
Association of Urology Congress last month. It compared withdrawal rates
associated with antimuscarinic drugs (both licensed and unlicensed in
the UK) based on 56 randomised placebo-controlled trials.
The meta-analysis showed a greater risk of withdrawal for oxybutynin
(relative risk 1.4 compared with placebo) than for tolterodine (relative
risk 0.7 compared with placebo) and no differences in rates when comparing
placebo with the newer agents solifenacin and darifenacin.
Data from a study involving 1,355 patients comparing tolterodine (4mg)
and solifenacin (5mg and 10mg) suggested a better outcome for patients
taking solifenacin, which was more effective in treating urge incontinence
(P=0.001) and was associated with less use of pads and fewer episodes
of incontinence. |
The
Pharmaceutical Journal
Acrobat
Reader